Welcome to our dedicated page for Advanced Biomed SEC filings (Ticker: ADVB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Advanced Biomed Inc. SEC filings document a Nevada emerging growth company with common stock listed on Nasdaq under ADVB. The filings identify the issuer’s biotechnology focus in precision medicine and advanced diagnostics and record material events affecting its capital structure, listed security and corporate organization.
Recent 8-K and amended 8-K filings cover securities purchase agreements, an equity line of credit, a short-term loan agreement, share issuances, the 1-for-20 reverse stock split and Nasdaq minimum-bid-price correspondence. They also document director and officer changes, material definitive agreements, completed acquisition or disposition activity, amendments to charter documents, and other formal disclosures tied to governance, financing and shareholder rights.
Advanced Biomed Inc. disclosed that it entered into a Securities Purchase Agreement with certain investors on January 28, 2026, to issue and sell 4,000,000 shares of common stock at $0.062 per share, for total proceeds of $248,000.
The transaction closed and the shares were issued on January 29, 2026. The shares were sold in a private placement relying on exemptions from U.S. registration under Section 4(a)(2) of the Securities Act and Regulation S.
Advanced Biomed Inc. entered into a Supplemental Agreement related to its previously announced spin-off of Advanced Biomed (HK) Limited. The Hong Kong subsidiary acknowledged that it owes the company an aggregate $6,925,549, reflecting its accounts receivable as of the original spin-off date and the new agreement date.
Under this Supplemental Agreement, Advanced Biomed (HK) Limited irrevocably agrees to repay the entire debt on or before the first anniversary of January 26, 2026. This supplements the prior deal in which Advanced Biomed agreed to sell 100% of the Hong Kong subsidiary’s shares for an aggregate purchase price of US$23,000. The board of directors unanimously approved the Supplemental Agreement.
Advanced Biomed Inc. obtained written consent from stockholders holding approximately 79.92% of its voting power to approve a reverse stock split of its common stock. The Board is authorized to implement a reverse split at a ratio ranging from 1-for-2 to 1-for-100, in its sole discretion, to increase the per-share trading price and help maintain the company’s listing on The Nasdaq Capital Market.
As of January 8, 2026, the company had 21,640,000 shares of common stock outstanding. The reverse split will reduce the number of shares each investor holds but is intended to leave each stockholder’s percentage ownership generally unchanged, with fractional shares rounded up to the nearest whole share. No change will be made to the number of authorized shares or the $0.001 par value. The action was approved by the Board on January 7, 2026 and will not become effective until after February 12, 2026, with the company currently anticipating an effective date of February 13, 2026 or a later date specified in a Certificate of Amendment filed in Nevada.
Advanced Biomed Inc. reported that it has failed to meet Nasdaq’s minimum bid price requirement of $1.00 per share by the January 14, 2026 compliance deadline. Nasdaq staff has notified the company that its common stock is scheduled for delisting and trading suspension on January 27, 2026 unless the decision is reversed.
The company appealed the delisting notice on January 21, 2026, which temporarily stayed any suspension and the filing of a Form 25-NSE while a Nasdaq Hearings Panel reviews the case. Advanced Biomed plans to present a remediation plan, including a reverse stock split that stockholders approved on January 12, 2026 and that is expected to become effective on or after February 13, 2026. The company cautions that there is no assurance the Panel will allow continued listing or that it will regain compliance within any time period that may be granted.
Advanced Biomed Inc. (ADVB) reported a continued operating loss as it advances oncology diagnostics development. For the three months ended September 30, 2025, the company recorded a net loss of $386,901, wider than $265,580 a year earlier, driven mainly by higher research and development spending.
Total operating expenses were $523,914, including $235,992 for research and development and $287,922 for general and administrative costs. Other income, largely foreign exchange gains, added $137,013, partially offsetting expenses. There was no income tax expense.
As of September 30, 2025, Advanced Biomed held cash of $2,656,519 and total assets of $6,242,970, against total liabilities of $3,238,846 and stockholders’ equity of $3,004,124. Operating activities used $610,342 of cash in the quarter. Management discloses substantial doubt about the company’s ability to continue as a going concern but notes support from its March 2025 IPO, which raised $6.56 million in gross proceeds, and an equity line of credit allowing sales of up to $25,000,000 of common stock.
Advanced Biomed Inc. reported an annual 10-K describing a pre-commercial precision oncology business built on a proprietary microfluidic platform and ultra‑sensitive biosensor technology for circulating tumor cell (CTC) capture, identification and single‑cell isolation. The company has completed an Initial Public Offering of 1,640,000 shares at $4.00 per share, generating approximately $5.49M net proceeds. Several products (A+Pre and AC-1000 and corresponding chips) are cleared by the NMPA, while additional instruments and four immunostaining kits are at registration application or review stages.
The filing discloses a consolidated net loss of $3,258,969 for the year and net cash used in operating activities of $5,825,055. Management states these conditions give rise to substantial doubt about going concern, and the company intends to raise additional capital, rely on forthcoming operations, and seek financial support from related parties. The company holds multiple granted patents in China, the U.S., and international PCT filings covering its chips and separation technologies, and reports progress on mass‑production trials with injection molding partners.
Advanced Biomed Inc. filed a current report describing that it issued a press release announcing the launch of its A+PerfusC™ integrated perfusion 3D cell culture platform for precision medicine and drug discovery. The filing mainly serves to furnish this press release as an exhibit for investors and other stakeholders.
Advanced Biomed Inc. filed a current report describing that it issued a press release announcing the launch of its A+PerfusC™ integrated perfusion 3D cell culture platform for precision medicine and drug discovery. The filing mainly serves to furnish this press release as an exhibit for investors and other stakeholders.